 |
13 Diseases |  |
3 Trials |
|
3 Trials |  |
113 News |  |
| «12 |
- | Arikayce (amikacin liposome inhalation suspension) / Insmed
Trial completion date: Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease (clinicaltrials.gov) - Feb 1, 2019
P2, N=30, Active, not recruiting, Sponsor: Kevin Winthrop
Trial completion date: Jun 2019 --> Dec 2019
- | Arikayce (amikacin liposome inhalation suspension) / Insmed
Trial primary completion date, Nontuberculous mycobacteria: CONVERT: Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone (clinicaltrials.gov) - Nov 20, 2018
P3, N=336, Active, not recruiting, Sponsor: Insmed Incorporated
Trial completion date: Jun 2019 --> Dec 2019 Trial primary completion date: May 2019 --> Jul 2017
- | Arikayce (amikacin liposome inhalation suspension) / Insmed
Enrollment closed, Trial completion date, Trial primary completion date: Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease (clinicaltrials.gov) - Jun 27, 2018
P2, N=30, Active, not recruiting, Sponsor: Kevin Winthrop
Trial primary completion date: May 2019 --> Jul 2017 Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Jun 2019 | Trial primary completion date: Sep 2019 --> Mar 2019
- |||| Arikayce (amikacin liposome inhalation suspension) / Insmed
Trial primary completion date, Nontuberculous mycobacteria: CONVERT: Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone (clinicaltrials.gov) - Mar 23, 2018
P3, N=350, Active, not recruiting, Sponsor: Insmed Incorporated
Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Jun 2019 | Trial primary completion date: Sep 2019 --> Mar 2019 Trial primary completion date: Oct 2017 --> May 2019
- ||||| Arikayce (amikacin liposome inhalation suspension) / Insmed
Enrollment closed, Trial primary completion date, Nontuberculous mycobacteria: CONVERT: Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone (clinicaltrials.gov) - Feb 7, 2017
P3, N=350, Active, not recruiting, Sponsor: Insmed Incorporated
Trial primary completion date: Oct 2017 --> May 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Oct 2017
- | Arikayce (amikacin liposome inhalation suspension) / Insmed
New P2 trial: Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease (clinicaltrials.gov) - Jan 30, 2017
P2, N=30, Recruiting, Sponsor: Kevin Winthrop
- Arikayce (amikacin liposome inhalation suspension) / Insmed
Phase classification: Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) (clinicaltrials.gov) - Nov 18, 2016
P1b/2a, N=0, Completed, Sponsor: Insmed Incorporated
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Oct 2017 Phase classification: P1/2 --> P1b/2a
- | Arikace (amikacin liposome inhalation suspension) / Insmed
Phase classification, Trial initiation date: Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa (clinicaltrials.gov) - Oct 3, 2016
P1b/2a, N=46, Completed, Sponsor: Insmed Incorporated
Phase classification: P1/2 --> P1b/2a Phase classification: P1/2 --> P1b/2a | Initiation date: Jun 2007 --> Jan 2008
- |||| Arikayce (amikacin liposome inhalation suspension) / Insmed
Trial completion, Trial primary completion date, Nontuberculous mycobacteria: Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria (clinicaltrials.gov) - Dec 12, 2015
P2, N=90, Completed, Sponsor: Insmed Incorporated
Phase classification: P1/2 --> P1b/2a | Initiation date: Jun 2007 --> Jan 2008 Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Jun 2015
- |||||||||| Arikayce (amikacin liposome inhalation suspension) / Insmed
New P3 trial, Nontuberculous mycobacteria: Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212 (clinicaltrials.gov) - Dec 11, 2015
P3, N=200, Enrolling by invitation, Sponsor: Insmed Incorporated
- ||||||| Arikace (amikacin liposome inhalation suspension) / Insmed
Trial completion: Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection (clinicaltrials.gov) - Dec 10, 2015
P3, N=206, Completed, Sponsor: Insmed Incorporated
Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Jun 2015 Active, not recruiting --> Completed
- | Arikace (amikacin liposome inhalation suspension) / Insmed
Enrollment closed, Trial primary completion date: Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection (clinicaltrials.gov) - Feb 19, 2015
P3, N=250, Active, not recruiting, Sponsor: Insmed Incorporated
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Jun 2015
- Arikayce (amikacin liposome inhalation suspension) / Insmed
Enrollment closed, Trial primary completion date, Nontuberculous mycobacteria: Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria (clinicaltrials.gov) - Feb 19, 2015
P2, N=89, Active, not recruiting, Sponsor: Insmed Incorporated
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Jun 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Apr 2014
- || Arikayce (amikacin liposome inhalation suspension) / Insmed
New P3 trial, Nontuberculous mycobacteria: CONVERT: Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone (clinicaltrials.gov) - Jan 22, 2015
P3, N=350, Recruiting, Sponsor: Insmed Incorporated
- Arikace (amikacin liposome inhalation suspension) / Insmed
Enrollment change, Trial withdrawal: Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa (clinicaltrials.gov) - Jan 12, 2015
P3, N=0, Withdrawn, Sponsor: Insmed Incorporated
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Apr 2014 N=300 --> 0 | Not yet recruiting --> Withdrawn
- ||||||| Arikace (amikacin liposome inhalation suspension) / Insmed
Trial completion: Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections (clinicaltrials.gov) - Mar 3, 2014
P3, N=302, Completed, Sponsor: Insmed
N=300 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- |||||| Arikace (amikacin liposome inhalation suspension) / Insmed
Enrollment open: Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection (clinicaltrials.gov) - Dec 10, 2012
P3, N=250, Recruiting, Sponsor: Insmed
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Arikayce (amikacin liposome inhalation suspension) / Insmed
Enrollment open, Nontuberculous mycobacteria: Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria (clinicaltrials.gov) - May 13, 2012
P2, N=100, Recruiting, Sponsor: Insmed
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Arikayce (amikacin liposome inhalation suspension) / Insmed
Enrollment change: Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) (clinicaltrials.gov) - May 2, 2012
P1/2, N=66, Completed, Sponsor: Insmed
Not yet recruiting --> Recruiting N=47 --> 66
- |||| Arikayce (amikacin liposome inhalation suspension) / Insmed
Trial completion: Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) (clinicaltrials.gov) - May 2, 2012
P1/2, N=66, Completed, Sponsor: Insmed
N=47 --> 66 Active, not recruiting --> Completed
- ||||| Arikace (amikacin liposome inhalation suspension) / Insmed
Trial initiation date: Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection (clinicaltrials.gov) - Mar 15, 2012
P3, N=250, Recruiting, Sponsor: Insmed
Active, not recruiting --> Completed Initiation date: Oct 2011 --> Oct 2012
- ||||| Arikace (amikacin liposome inhalation suspension) / Insmed
Trial initiation date: Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections (clinicaltrials.gov) - Feb 20, 2012
P3, N=302, Completed, Sponsor: Insmed
Initiation date: Oct 2011 --> Oct 2012 Initiation date: Jul 2011 --> Mar 2012